The FDA has granted a quick review for three psychedelic drug trials. The trials are reportedly related to treating depression, although the status of other potential treatments, such as MDMA-assisted therapy for PTSD, is unclear as it has been rejected. The development is part of a broader focus on mental health initiatives and treatments.